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Medicines indicated for the treatment of peptic ulcer and GERD are H2 blockers, proton pump inhibitors, 
antacids and mucoprotective agents. The analysis of the market of the medicines used for treatment of peptic 
ulcer and GERD, implies analysis of the range of these medicines registered in RNM, their presence on the list 
of medicines which costs are covered by the Health Insurance Fund, their financial and physical availability, as 
opposed to treatment recommendations of the above conditions according to MBD as well as a comparison of 
the range of these drugs available on the world markets.  For the analysis of the consumptions of drugs issued 
at the expense of the Health Insurance Fund in pharmacies of the Republic of North Macedonia for a period of 
four years by number of realized prescriptions and total amounts of funds, we used the data published on the 
official website of the  Health Insurance Fund of RNM. The increase in the total number of prescription drugs 
is probably due to the large number of patients diagnosed with peptic ulcer and GERD, as well as the recent 
regimen for issuing such medicines without a prescription. The total amounts for issued medicines at the 
expense of the Health Insurance Fund depend on the price and the number of issued prescriptions. The RNM 
is a county with a low standard and limited budget for medicine, in which the health policies are oriented 
towards saving the funds for procurement of drugs. 




Peptic ulcer - is a damage or lesion in the mucosa 
of the digestive tract, typically in the stomach or 
duodenum. 
Gastroesophageal reflux disease - as a 
consequence of the return of gastric acid and the 
remaining gastric contents, there is a burning 
sensation in the chest, which can sometimes be 
accompanied by severe pain. 
The analysis of the market of medicnes used for 
the treatment of peptic ulcer and 
gastroesophageal reflux, includes analysis of the 
range of these medicnes registered in our 
country, their presence on the List of medicines 
for which costs are covered by the Health 
Insurance Fund, financial and physical 
availability, as opposed to recommendations for 
treatment of the above conditions according to 
Evidence-Based Medicine as well as a 
comparison of the range of these medicines 
available on the world market. 
Peptic ulcer occurs as a result of the inability of 
the gastroduodenal mucosa to protect epithelial 
cells from the action of hydrochloric acid and the 
enzyme pepsin. 
The peptic ulcer may occur as a result of the 
following factors: hypersecretion of hydrochloric 
acid and pepsin, presence of Helicobacter pylori, 
certain medications, genetic factors and lifestyle 
factors. The most common complication of ulcer 
disease that occurs as an accompanying 
symptom is gastrointestinal bleeding. 
Gastroesophageal reflux disease is a 
consequence of weakness of the lower 
esophageal sphincter, which forms a ring around 
the lower esophagus. Causes that can lead to 
weakness of the lower esophageal sphincter are: 
application of certain drugs (beta blockers, 
calcium channel blockers, nitrates, estrogen, 
progesterone), smoking, emotional stress, 
improper chewing . 
The most serious complication that can occur in 
patients as a result of constant exposure to acid 
reflux is Barrett’s esophagus. 
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Table 1: Pharmacotherapy 




➢ Non-pharmacological methods 
 
➢ Non-pharmacological methods 
 
➢ Pharmacological methods 
 






Proton pump inhibitors H2 blockers 
 
 Prokinetic drugs 
 
Eradication of Helicobacter pylori: 
✓ Antibiotics- Triple therapy 
 
Proton pump inhibitors 
 
 In patients with resistant and complicated 
gastroesophageal reflux disease: 




The main objectives of this paper are: 
To make an analysis of the range of medicines 
used for the treatment of peptic ulcer and 
Gastroesophageal reflux on the market in the 
Republic of North Macedonia compared to the 
registered medicines in the world. 
To compare the registered medicines in RNM and 
the medicines for which the costs are covered by 
the Health Insurance Fund of RNM,  with the 
recommendations from Medicine based on 
evidence for medicine treatment of the above 
conditions. 
To analyze the consumption of medicines for 
which the costs are covered by the Health 
Insurance Fund in the pharmacies of RNM in the 
period from 2015 to 2018 by number of realized 
prescriptions and total paid amount of funds per 
medicine.  
To perceive the physical and financial availability 
of the recommended medicines to patients and 
doctors as an opportunity to choose the most 
appropriate medicine 
 
MATERIALS AND METHODS  
In order to achieve the set goals, we reviewed 
relevant literary data from primary, secondary 
and tertiary literature, the recommendations of 
Evidence-Based Medicine, official data from 
international and national  medicine registers and 
the published reports on medicine consumption 
from the  List of medicines which costs are 
covered by the Health Insurance Fund . 
For analysis of the consumption of drugs issued at 
the expense of the Fund in the pharmacies of 
RNM in the period from 2015 to 2018 by number 
of realized prescriptions and total paid amount of 
funds per drug, we used the data published on 
the official website of the Health Insurance Fund. 
 
RESULT AND DISCUSSION 
Obtained results are presented on Table 2, Table 
3, Figure 1 and Figure 2.  
Table 2: Medicines used for the treatment of peptic ulcer and gastroesophageal reflux in RNM 
which costs are covered by Health Insurance Fund 
ATC code International 
nonproprietary name -
INN 





A02BA02 Ranitidine 0,3 g O Tablets  
A02BA03 Famotidine  40 mg O Tablets 
A02BC01 Omeprazole 20 mg O Capsules 
A02BC02 Pantoprazole  40 mg O Tablets 
A02BC03 Lansoprazole 30 mg O Capsules 
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Table 3: Recommended drugs for treatment of peptic ulcer and gastroesophageal reflux according 







Registered medicine in 
RNM 
Medicines which costs 



























Comparison of the consumption of H2 blockers and proton pump inhibitors in RNM in relation to 
realized prescriptions for a period of four years 
 
Fig.1: Realized prescriptions for a period of four years ( 2015-2018) 
 
In the examined period: 
The most commonly prescribed drug is: Ranitidine 150 mg 
The largest increase in prescribed recipes is observed for: Pantoprazole 20 mg and Pantoprazole 40 
mg 
The least prescribed drugs are: Lansoprazole 15 mg and Famotidine 20 m  
Comparison of the consumption of H2 blockers and proton pump inhibitors in the Republic of North 
Macedonia in relation to the total amount by the HIF  
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Fig.2: Presentation of the realized amount for the period 2015-2018 
 
The largest amount of funds are paid for: 
Lansoprazole 30 mg - 24,358,758 denars (2018) 
The largest increase in funds paid for: 
Pantoprazole 40 mg - increase of 274.7%,  
Pantoprazole 20 mg - increase of 223.7% 
Decreased value in funds paid for: Omeprazole 
20 mg - reduced by 9.67%, Famotidine 20 mg - 
reduced by 9.58% 
 
CONCLUSION 
10 INN medicnes for treatment of ulcer disease 
and gastroesophageal reflux have been 
registered in the Republic of  North Macedonia, 
with a total of 40 names and 9 dosage forms. 
Compared to the world market, according to 
current knowledge there are about fifty medicines 
from this group that are not registered in our 
country.The list of the medicines which costs are 
covered ny the Health Insurance Fund  includes 
five INN medicines for the treatment of peptic 
ulcer  and gastroesophageal reflux. All medicines 
which are recommended according to MBD are 
on the market in RNM. 
The supply of insured persons with medicines 
used for the treatment of peptic ulcer and GERD 
is continuously moving upwards. 
In the period from 2015 to 2018, most of the 
prescriptions were realized for Ranitidine, while 
the largest amounts were paid for Lansoprazole 
30 mg 
In the last ten years, in order to save funds in the 
Republic of N. Macedonia, the principle of 
generic drug policy has been implemented. 
Newer generation mediciness are lacking on the 
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